D
Regeneron Pharmaceuticals, Inc. REGN
$607.59 $1.980.33% NASDAQ
Recommendation
Prev Close
$605.61
Volume
26,315
Avg Vol (90D)
1,006,670
Market Cap
$63.99B
Dividend & Yield
$0.88(0.15%)
52-Week Range
$525.99 - $1,211.20
P/E (TTM)
15.41
EPS (TTM)
$39.29
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
3/13/2025 - MarketBeat
Aspire Growth Partners LLC Makes New $421,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
5/5/2025 - MarketBeat
Mercer Global Advisors Inc. ADV Has $16.66 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
5/5/2025 - MarketBeat
Comerica Bank Sells 1,364 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
5/5/2025 - MarketBeat
Voleon Capital Management LP Makes New $478,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
5/4/2025 - MarketBeat
Cantor Fitzgerald Issues Positive Outlook for REGN Earnings
5/3/2025 - MarketBeat
Westbourne Investments Inc. Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
5/3/2025 - MarketBeat
Comerica Bank Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
5/3/2025 - Ticker Report
UBS Group Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $633.00
5/2/2025 - MarketBeat
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
5/2/2025 - Zacks Investment Research
Schonfeld Strategic Advisors LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
5/2/2025 - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Itau Unibanco Holding S.A.
5/2/2025 - Ticker Report
AQR Capital Management LLC Sells 18,449 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
5/2/2025 - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold Rating by StockNews.com
5/2/2025 - Ticker Report
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): 'Arguably The Most Innovative Biopharma Company I've Seen In The Last Two Decades'
5/1/2025 - Insider Monkey
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences
5/1/2025 - Simply Wall St
Regeneron Pharmaceuticals (REGN) Price Target Lowered by Guggenheim REGN Stock News
5/1/2025 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Quarterly Earnings Results, Misses Expectations By $0.61 EPS
5/1/2025 - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Issues Quarterly Earnings Results, Misses Expectations By $0.61 EPS
5/1/2025 - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down Following Weak Earnings
5/1/2025 - MarketBeat
REGN June 13th Options Begin Trading
5/1/2025 - Stock Options Channel
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
5/1/2025 - Zacks Investment Research
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
5/1/2025 - Globe Newswire
Dupixent (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
5/1/2025 - Globe Newswire
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?
2/27/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$14.09B
EBITDA (TTM)
$4.46B
EBIT (TTM)
$3.96B
Net Income (TTM)
$4.50B
Balance Sheet
Total Assets (Q)
$37.55B
Total Debt (Q)
$2.70B
Total Liabilities (Q)
$8.16B
Book Value Per Share (Q)
$277.50
Cash Flow
Cash from Operations (TTM)
$3.95B
Cash from Investing (TTM)
-$133.50M
Cash from Financing (TTM)
-$3.34B
Net Change in Cash (TTM)
$483.20M
Filings
Filing Date
Tuesday, April 29, 2025
Period Date
Monday, March 31, 2025
Next Filing
Beginning of August (est)
Price History
Loading...
Beta
0.66
7-Day Total Return
1.31%
30-Day Total Return
-7.73%
60-Day Total Return
-15.74%
90-Day Total Return
-13.32%
Year to Date Total Return
-14.93%
1-Year Total Return
-36.43%
2-Year Total Return
-24.25%
3-Year Total Return
-7.89%
5-Year Total Return
12.28%
52-week Low
Apr 09, 2025 - $525.99
52-week High
Aug 27, 2024 - $1,211.20
Valuation
Market Cap
$63.99B - Large Cap
Enterprise Value
$49.07B
Price/Sales (TTM)
4.78
Price/Book (Q)
2.18
Dividends and Shares
Shares Outstanding
111.20M
Dividend Per Share (Most Recent)
$0.88
Dividend Per Share (TTM)
$0.88
Corporate Info
Website
www.regeneron.com
Phone Number
914 847 7000
Address
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
Country
United States
Year Founded
1988
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to... more
NASDAQ 05/05/2025 9:42AM Eastern Quotes delayed